Robert McCroskey

Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial

Saad Z. Usmani, Fredrik Schjesvold, Albert Oriol et al. · The Lancet Haematology · 2019 · 237 citations · Full text

Hematological Malignancy, Medicine, Immunology +7

Pemetrexed with or without Matuzumab as Second-Line Treatment for Patients with Stage IIIB/IV Non-small Cell Lung Cancer

Joan H. Schiller, Joachim von Pawel, Philipp Schütt et al. · Journal of Thoracic Oncology · 2010 · 51 citations · Full text

Second-line Treatment, Oncology, Pathology +6

acute tumor lysis syndrome and treatment response in patients treated for refractory chronic lymphocytic leukemia with short-course, high-dose cytosine arabinoside, cisplatin, and etoposide

Robert McCroskey, Deane F. Mosher, Cory D. Spencer et al. · Cancer · 1990 · 45 citations · Full text

High-dose busulfan, melphalan, thiotepa and peripheral blood stem cell infusion for the treatment of metastatic breast cancer

K Schiffman, Leona Holmberg, FR Appelbaum et al. · Bone Marrow Transplantation · 1997 · 30 citations

Metastatic Breast Cancer, Oncology, Breast Oncology +8

Antiphospholipid antibodies and adrenal hemorrhage

Robert McCroskey, A.P. Phillips, Frank E. Mott et al. · American Journal of Hematology · 1991 · 23 citations

Thrombosis, Autoimmune Disease, Cardiovascular Disease +13